Skip to main content

$0.059 -0.003 (-4.84%)

High

$0.06

Low

$0.06

Trades

100

Turnover

$254,071

Volume

4,352,698
30 June 2023 at 4:10pm
Register to track ANP and receive email alerts.
Subject
ANP Ann: Proposed issue of securities - ANP

ANP Ann: Positive PDCO opinion and A$20m Placement

ANP Ann: 2021 Annual Report

ANP Ann: Appendix 4G and Corporate Governance Statement

ANP Ann: Quarterly Report and Appendix 4C

ANP Ann: Trading Halt

ANP Ann: Initial Director's Interest Notice

ANP Ann: Antisense Therapeutics appoints new Non-Executive Director

ANP Ann: Positive feedback received on Paediatric Investigation Plan

ANP Ann: New data supports ATL1102s broader clinical potential

ANP Ann: ANP to present new proteomics data at WMS Congress 2021

ANP Ann: Appendix 4E and Full Year Statutory Accounts

ANP Ann: ANP to participate in development of DMD Guidance for FDA

ANP Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD

ANP Ann: Quarterly Report and Appendix 4C

ANP Ann: Antisense Therapeutics transitions to new Board Chair

ANP Ann: ANP and MCRI new R&D collaboration for ATL1102

ANP Ann: ATL1102 for DMD EMA PIP feedback and FDA regulatory progress

ANP Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US

ANP Ann: Manufacture of ATL1102 clinical supplies for Phase IIb trial

ANP Ann: Appendix 2A & Cleansing Notice

ANP Ann: Proposed issue of Securities - ANP

ANP Ann: Quarterly Report and Appendix 4C

ANP Ann: US FDA Type C Meeting for ATL1102 in DMD

ANP Ann: Initial Director's Interest Notice - CG

ANP Ann: Antisense Therapeutics appoints new Non-Executive Director

ANP Ann: Appendix 3G

ANP Ann: FDA Rare Disease Day 2021

ANP Ann: Jett Foundation 4th Annual Rare Disease Day

ANP Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA

ANP Ann: Company Secretary Appointment

ANP Ann: Half Yearly Report and Half Year Accounts

ANP Ann: ANP meeting with US FDA granted for ATL1102 in DMD

ANP Ann: Quarterly Update and Appendix 4C

ANP Ann: Appendix 2A

ANP Ann: Proposed issue of Securities - ANP

ANP Ann: Change of Registered Office and Principal Place of Business

ANP Ann: Ceasing to be a substantial holder

ANP Ann: Results of Annual General Meeting

ANP Ann: Annual General Meeting Chairman's Address

ANP Ann: 2020 Annual General Meeting Presentation

ANP Ann: EC grants Orphan Drug Designation for ATL1102 in DMD

ANP Ann: Receipt of R&D Tax Incentive payment

ANP Ann: Ceasing to be a substantial holder

ANP Ann: Change of Director's Interest Notice (x 2)

ANP Ann: Appendix 2A and 708A notice

ANP Ann: ANP to present at Several Upcoming Virtual Conferences

ANP Ann: Antisense Therapeutics closes SPP oversubscribed

ANP Ann: Antisense Therapeutics to present at Australian Equities Day

ANP Ann: Reminder - Antisense Therapeutics SPP Closing Date

Register to track ANP and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL